Therapeutic Asset Ratings
308 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE
Melanoma
H. Lee Moffitt Cancer Center and Research Institute
P1
CC
(40)
bat4706
Melanoma
Bio-Thera Solutions
P1
CC
(40)
cft1946
Melanoma
C4 Therapeutics, Inc.
P1
CC
(40)
Ganciclovir
Melanoma
Gene Surgery LLC
P1
CC
(40)
gme751
Melanoma
Sandoz
P1
CC
(40)
Stimotimagene Copolymerplasmid
Melanoma
Gene Surgery LLC
P1
CC
(40)
PRT1419
Melanoma
Prelude Therapeutics
P1
C
(39)
ltt462
Melanoma
Novartis Pharmaceuticals
P2
C
(37)
Acc-1898
Melanoma
AccSalus Biosciences, Inc.
P1
C
(37)
ai-061
Melanoma
OncoC4, Inc.
P1
C
(37)
autologous CD3+ enriched T lymphocytes obtained from peripheral blood mononuclear cells (PBMCs) by apheresis. The cells are transduced with a self-inactivating, non-replicating lentiviral vector encoding an enhanced-affinity T cell receptor (TCR) targeting the HLA-A*02:01-restricted MAGE-A4 peptide (GVYDGREHTV) alongside the CD8 alpha (CD8?) co-receptor. The expressed transgene comprises the coding sequence for the CD8? co-receptor, separated by a foot-and-mouth disease virus 2A self-cleaving peptide sequence from the coding sequence of the MAGE-A4 T-cell receptor alpha and beta chains that are separated from each other by a porcine teschovirus-1 2A self-cleaving peptide sequence, under control of the human elongation factor 1 alpha (EF-1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a tRNA primer binding site, a ? packaging signal, a truncated gag, a Rev response element (RRE) and a central polypurine tract (cPPT) sequence 5' to the transgene, and a polypurine tract (PPT) 3' to the transgene. The vector is pseudotyped with the vesicular stomatitis virus (VSV) G envelope glycoprotein. The CD3+ T lymphocytes are purified and activated using anti-CD3/anti-CD28 monoclonal antibody coated magnetic beads. The cells are then cultured in media containing interleukin 2 (IL-2), human AB serum and a protein kinase B (AKT inhibitor). The cells are CD3+ (> 80%), express the high affinity MAGE-A4 specific TCR and CD8? co-receptor (CD8? +TCR+; >16%) and are cytotoxic to MAGE-A4 expressing tumor cells
Melanoma
USWM CT, LLC
P1
C
(37)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Melanoma
USWM CT, LLC
P1
C
(37)
Autologous Total Tumor Mrna Loaded Dotap Liposome Vaccine
Melanoma
University of Florida
P1
C
(37)
b7-h3 car t cells
Melanoma
St. Jude Children's Research Hospital
P1
C
(37)
ba1302
Melanoma
Shandong Boan Biotechnology Co., Ltd
P1
C
(37)
Bdc-3042
Melanoma
Bolt Biotherapeutics, Inc.
P1
C
(37)
Belvarafenib
Melanoma
Genentech, Inc.
P1
C
(37)
bi 3810944
Melanoma
Boehringer Ingelheim
P1
C
(37)
bi 765063
Melanoma
Boehringer Ingelheim
P1
C
(37)
bi 770371
Melanoma
Boehringer Ingelheim
P1
C
(37)
bmc128
Melanoma
Biomica Ltd.
P1
C
(37)
Claturafenib
Melanoma
Pfizer
P1
C
(37)
Dcc-3084
Melanoma
Deciphera Pharmaceuticals, LLC
P1
C
(37)
Definity
Melanoma
Sunnybrook Health Sciences Centre
P1
C
(37)
dky709
Melanoma
Novartis Pharmaceuticals
P1
C
(37)
Showing 201 to 225 of 308 assets
Previous
Page 9 of 13
Next